FRI156 Novel Radiolabeled Ligand, Para-chloro-2-[18F]fluoroethyletomidate (CETO) Is Equivalent To [11C]metomidate-PET (MTO) For The Lateralisation Of Primary Aldosteronism (PA)
Emily Goodchild(St Bartholomew's Hospital), Morris J. Brown(St Bartholomew's Hospital), Victoria Warnes(Cambridge University Hospitals NHS Foundation Trust), Kate Laycock(St Bartholomew's Hospital), Jackie Salsbury(Queen Mary University of London), Russell Senanayake(University of Cambridge), Giulia Argentesi(St Bartholomew's Hospital), Waiel Bashari(University of Cambridge), Franklin I. Aigbirhio(University of Cambridge), Daniel Gillett(Cambridge University Hospitals NHS Foundation Trust), Mark Gurnell(University of Cambridge), Anju Sahdev(St Bartholomew's Hospital), Xilin Wu(St Bartholomew's Hospital), William M Drake(St Bartholomew's Hospital), Kennedy Cruickshank, Nicholas J. Bird(Cambridge University Hospitals NHS Foundation Trust), James McFarlane(University of Cambridge), S Hader, István Boros(University of Cambridge), Heok Cheow(Cambridge University Hospitals NHS Foundation Trust), Samuel O’Toole(Royal Hallamshire Hospital)
Cited by 0
Related Papers
Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors
|European Journal of Endocrinology|2016|1.5k
Traumatic brain injury: progress and challenges in prevention, clinical care, and research
|The Lancet Neurology|2022|1.3k
Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort
|The Lancet Diabetes & Endocrinology|2017|951
Treatment of Acromegaly with the Growth Hormone–Receptor Antagonist Pegvisomant
|New England Journal of Medicine|2000|874